Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium
Open Access
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 74 (1) , 200-219
Abstract
No abstract availableKeywords
Funding Information
- European Commission
This publication has 158 references indexed in Scilit:
- GOLD classifications and mortality in chronic obstructive pulmonary disease: the HUNT Study, NorwayThorax, 2013
- Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic FactorsAmerican Journal of Gastroenterology, 2012
- Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statementAlimentary Pharmacology & Therapeutics, 2011
- Oral Tolvaptan Is Safe and Effective in Chronic HyponatremiaJournal of the American Society of Nephrology, 2010
- Clinical trial: short‐term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double‐blind, placebo‐controlled studyAlimentary Pharmacology & Therapeutics, 2010
- Impact of pretransplant hyponatremia on outcome following liver transplantation #Hepatology, 2009
- CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care settingAmerican Journal of Infection Control, 2008
- A Propensity Matched Study of New York Heart Association Class and Natural History End Points in Heart FailureThe American Journal of Cardiology, 2007
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Prognostic value of spontaneous hyponatremia in cirrhosis with ascitesDigestive Diseases and Sciences, 1976